A Eficácia da Suplementação com Probióticos no Stress e na Ansiedade (PROfoS)
A Eficácia da Suplementação com Probióticos no Stress e na Ansidade - Um Estudo de Intervenção Randomizado e Controlado por Placebo em Estudantes Saudáveis Durante o Período de Exames.
This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of 8-week supplementation with a probiotic combination of Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 (total daily dose of 1 × 10¹⁰ CFU) compared with matching placebo in healthy university students during the examination period. The study aimed to determine whether probiotic supplementation reduced perceived stress and anxiety and improved related psychological parameters.
The primary outcomes were changes in Perceived Stress Scale (PSS-10) scores from baseline to weeks 5 and 8, compared with placebo. Secondary outcomes included changes in Depression Anxiety Stress Scales-21 (DASS-21) subscales (Stress, Anxiety, and Depression), State-Trait Anxiety Inventory - State scale (STAI-S), Sense of Coherence Scale (SOC-29), Pittsburgh Sleep Quality Index (PSQI), self-reported gastrointestinal symptoms assessed using a Likert scale, and the incidence of adverse events during the 8-week intervention.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
The gut-brain axis enables bidirectional communication between the gastrointestinal tract and the central nervous system. Emerging evidence suggests that selected probiotic strains (psychobiotics) may modulate stress responses and emotional regulation. University examination periods constitute a predictable model of transient psychological stress in otherwise healthy individuals.
This randomized, double-blind, placebo-controlled study investigated whether daily supplementation with a probiotic combination of Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 reduced perceived stress and improved psychological parameters in healthy students exposed to exam-related stress. A total of 242 male and female students aged 18-40 years were randomized at the Medical University of Lublin, Poland. The final inclusion criteria required at least moderate stress (Depression Anxiety Stress Scales-21 [DASS-21] Stress score ≥10) and a DASS-21 Depression score ≤9. A preliminary screening involving 100 students indicated that the originally proposed DASS-21 Anxiety criterion (score 6-13) was overly restrictive, substantially reducing the number of eligible students. Consequently, this criterion was removed before the commencement of formal recruitment and randomization. All participants enrolled in the randomized trial were assessed according to the same revised eligibility criteria.
After providing electronic informed consent and confirming eligibility through online screening, participants were randomized in a 1:1 ratio to receive either a probiotic formulation containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 (total daily dose of 1 × 10¹⁰ colony-forming units) or a matching placebo. Written informed consent was obtained at the baseline visit before dispensing the study product.
The investigational product and placebo were identical in appearance and administered orally once daily (two capsules) for 8 weeks. Randomization was computer-generated, and both participants and investigators remained blinded to treatment allocation throughout the study. The intervention was scheduled to begin approximately six weeks before the first academic examination.
Study assessments were conducted at baseline, at week 5 (approximately one week before the first examination), and at week 8 (before a subsequent examination, with a ±3-day assessment window). Psychological and functional parameters were collected using validated self-report instruments administered electronically, with selected assessments performed during on-site visits. Participants were asked to maintain their usual diet, physical activity, and caffeine intake during the study period. Safety and tolerability were monitored throughout the intervention, and adverse events were recorded using an electronic reporting system with daily reminders.
The study was originally powered to detect clinically meaningful differences between groups in perceived stress levels. Statistical analyses included covariance-based models adjusted for baseline values and relevant covariates, together with longitudinal analyses. All participant data were coded to ensure confidentiality and handled in accordance with applicable data protection regulations.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Lublin, Polônia
- University of Lublin, Faculty of Health Sciences
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female students aged 18-40 years
- At least moderate stress (DASS-21 Stress score ≥10)
- No clinical depression (DASS-21 Depression score ≤9)
- Willingness to maintain usual diet, physical activity, and intake of caffeinated beverages during the study
- Written informed consent
Exclusion Criteria:
- Irritable bowel syndrome (Rome IV criteria) or any chronic intestinal disease (including celiac disease)
- Known food allergies, immunodeficiency disorders, or immunosuppressive treatment
- Antibiotic use within 4 weeks prior to screening
- Any psychiatric illness within the past 5 years
- Any malignant disease or autoimmune or allergic diseases (e.g., atopic dermatitis, asthma)
- Use of systemic psychotropic medications or steroids; use of topical corticosteroid creams within 4 weeks prior to screening
- Pregnancy, breastfeeding, or plans to become pregnant during the study
- Probiotic or prebiotic consumption or planned dietary changes within 4 weeks prior to screening
- Heavy caffeine consumption (>4 cups of 300 mL coffee per day)
- Drug or alcohol addiction or regular use of recreational drugs
- Smoking more than 10 cigarettes per day
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Probiotic
Two capsules containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 will be administered orally once daily (total daily dose of 1 × 10¹⁰ colony-forming units) for 8 weeks. |
Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 |
|
Comparador de Placebo: Placebo
Maltodextrin will be used as a placebo. The placebo capsules will be identical in appearance to the probiotic capsules and will be administered orally once daily (two capsules) for 8 weeks. |
Maltodextrin |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in perceived stress score
Prazo: Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo
|
Perceived stress will be assessed using the 10-Item Perceived Stress Scale (PSS-10), a validated questionnaire measuring the degree to which situations in one's life are appraised as stressful. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels (worse outcome). Changes in the total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in stress, anxiety and depression scores
Prazo: Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Stress, anxiety, and depression will be assessed using the Depression Anxiety Stress Scales - 21 Items (DASS-21). The DASS-21 consists of three subscales (Depression, Anxiety, and Stress), each including 7 items. Scores for each subscale range from 0 to 42 after standard score multiplication, with higher scores indicating greater symptom severity (worse outcome). Changes in the Stress, Anxiety, and Depression subscale scores from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in sleep quality score
Prazo: Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire measuring sleep quality over the previous month. The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). Changes in the PSQI global score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in severity of gastro-intestinal symptoms
Prazo: Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
|
The severitty of gastro-intestinal symptoms will be assessed with the use of 4-point Likert scale (0 - no symptom, 1 - weak, 2 - moderate, 4 - severe). The following symptoms will be assessed: abdominal pain, flatulence, nausea. |
Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
|
|
Incidence of treatment-emergent adverse events (Safety and Tolerability)
Prazo: From baseline through the 8-week intervention period.
|
Safety and tolerability will be assessed by monitoring the incidence of adverse events throughout the study. Adverse events will be self-reported by participants using an electronic reporting platform, which provides daily reminders for study product intake and allows participants to record any symptoms or adverse events experienced during the study period. |
From baseline through the 8-week intervention period.
|
|
Change in sense of coherence score
Prazo: Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 8 (±3 days) compared to placebo.
|
Sense of coherence will be assessed using the Sense of Coherence Scale - 29 Items (SOC-29), a validated questionnaire measuring psychological resilience and the ability to cope with stress. The total score ranges from 29 to 203, with higher scores indicating a stronger sense of coherence (better outcome). Changes in the SOC-29 total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 8 (±3 days) compared to placebo.
|
|
Change in state anxiety score
Prazo: Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.
|
State anxiety will be assessed using the State-Trait Anxiety Inventory - State version (STAI-S, also referred to as STAI X-1), a validated questionnaire measuring the current level of anxiety. The STAI-S total score ranges from 20 to 80, with higher scores indicating higher levels of anxiety (worse outcome). Changes in the STAI-S total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Emilia Majsiak, PhD, Medical University of Lublin
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- CT/NB/180/2025/PR-MS
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
No formal plan for sharing individual participant data has been established. The study data are retained by the Principal Investigator and are not publicly available due to participant confidentiality and data protection considerations.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .